Cue Biopharma, Inc.
NASDAQ:CUEBiotechnology
+$0.38 today
- Market cap
- $102.43M
- Beta
- 2.53
- P/E (TTM)
- -6.7
- EPS (TTM)
- -$4.06
Volume 0.21M
Average 0.74M
CUE Investing Cash Flow
Net cash used in or generated by investments in assets, acquisitions, and securities.
Cue Biopharma, Inc.NASDAQ: CUE
Investing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Investing cash flow dips below year-ago levels
Q1 FY2026 investing cash flow of $121K (cash outflow) fell 19.3% year over year, behind the +265.1% change in trailing-twelve-month investing cash flow.
Context
- Investing cash flow amounted to 0.3% of revenue in FY2025, unchanged from a year earlier.
- Investing cash flow increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -19.3% toward the trailing-twelve-month pace of +265.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Investing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 75K USD
- Year-over-year change
- +134.4%
- 4-year CAGR
- -69.9%
| Period | Period end | Investing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 75K | +134.4% |
| FY2024 | 2024-12-31 | 32K | -99.9% |
| FY2023 | 2023-12-31 | 25M | +201.6% |
| FY2022 | 2022-12-31 | (24.61M) | -370.2% |
| FY2021 | 2021-12-31 | 9.11M | — |
Investing Cash Flow vs competitors
How CUE compares with its peers on the latest reported figures
- CUE's LTM Mar 2026 investing cash flow of $104K is the 4th largest of the 7 companies compared; the peer median is $22.5K.
- Its year-over-year change of +265.1% is the 2nd highest of 4, against a peer median of -100.2%.
- Investing cash flow amounts to 0.3% of revenue for CUE, versus a peer median of 41.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $33.04M | -151.7% | — | — | |
| LTM Mar 2026 | $3.02M | — | +555.0% | 131.8% | |
| LTM Mar 2026 | $591.52K | +491.5% | — | 41.8% | |
| LTM Mar 2026 | $104K | +265.1% | — | 0.3% | |
| LTM Mar 2026 | $35K | -100.2% | -37.9% | — | |
| LTM Mar 2026 | $10K | — | — | — | |
| LTM Mar 2026 | $3 | — | — | 0.0% | |
| Peer median (excluding CUE) | $22.5K | -100.2% | +258.5% | 41.8% | |
Competitors are the stored peer set for CUE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (44.16M) | (53.01M) | (50.73M) | (40.67M) | (26.6M) |
| Depreciation & Amortization | (1.78M) | 1.81M | 3.44M | 2.35M | 958K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 11.52M | 9.5M | 8.18M | 6.85M | 4.74M |
| Change in Working Capital | (4.39M) | 356K | (934K) | (4.93M) | (3.3M) |
| Accounts Receivables | (1.73M) | 3.09M | (1.64M) | 753K | (6.5M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 520.4K | 83K | 770K | (678K) | 1.13M |
| Other Working Capital | (3.18M) | (2.81M) | (63K) | (5M) | 2.08M |
| Other Non-Cash Items | (26.13K) | (454K) | 90K | 74K | 2.51M |
| Operating Cash Flow | (38.84M) | (41.81M) | (39.96M) | (36.33M) | (21.69M) |
| Capital Expenditures | (913.04K) | (171K) | 0 | (66K) | (177K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 40K |
| Purchases of Investments | 0 | (29.45M) | 0 | 0 | (16.5M) |
| Sales of Investments | 10M | 5M | 25M | 0 | 16.5M |
| Other Investing Activities | 21.55K | 6K | 2K | 98K | 212K |
| Investing Cash Flow | 9.11M | (24.61M) | 25M | 32K | 75K |
| Debt Repayment | 0 | 10M | (2M) | (4M) | (4.5M) |
| Common Stock Issued | 17.38M | 39.3M | 13.39M | 14.22M | 30.79M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.85M | 4.36M | 473K | 18K | 0 |
| Financing Cash Flow | 19.23M | 53.66M | 11.86M | 10.24M | 26.29M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (10.5M) | (12.76M) | (3.1M) | (26.05M) | 4.68M |
| Free Cash Flow | (39.75M) | (41.98M) | (39.96M) | (36.4M) | (21.86M) |
Cue Biopharma, Inc.
NASDAQ:CUE
Intrinsic Alpha fair value
Locked
Current Price
$14.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.